Today: 30 June 2026
Tesla stock slides after delivery miss and BYD upset — what TSLA investors watch next

Tesla stock slides after delivery miss and BYD upset — what TSLA investors watch next

NEW YORK, January 4, 2026, 05:03 ET — Market closed

Tesla (TSLA) shares closed Friday down 2.6% at $438.07 after trading between $435.33 and $462.42. Tesla said fourth-quarter deliveries — vehicles handed to customers — totaled 418,227, including 406,585 Model 3 and Model Y cars, while production reached 434,358; it reported 2025 deliveries of 1,636,129. The company reported record fourth-quarter energy storage deployments of 14.2 gigawatt-hours (GWh), a measure of battery capacity, and said 2025 deployments totaled 46.7 GWh.

The delivery update is one of the first hard demand readings for the EV sector in the new year. It puts the focus back on whether Tesla can stabilize volumes as competition tightens and buyers remain price-sensitive.

Deliveries matter because they feed directly into revenue and factory utilization, especially when pricing is moving. With the stock tied to long-dated expectations for self-driving software and robotics, near-term demand surprises tend to hit sentiment fast.

A Form 8-K filing showed Tesla furnished the production-and-deliveries press release under Item 2.02, a section used to report operating results and related updates.

Analysts had expected about 434,487 deliveries for the quarter, according to Visible Alpha. The end of a $7,500 U.S. tax credit in September has weighed on demand, and China’s BYD overtook Tesla as the world’s top EV seller on an annual basis. “It’s about Optimus, Robotaxi and physical AI,” said Dennis Dick, a trader at Triple D Trading, which owns Tesla shares. Reuters

Europe added to the mixed picture. Tesla registrations fell 66% in France in December to 1,942 vehicles, while Sweden data showed a 71% drop to 821, Reuters reported. Norway bucked the trend, with registrations up 89% to 5,679, and Tesla’s 2025 market share there above 19%.

Rivian’s latest figures underscored the same demand strain for higher-priced EVs. The company reported 2025 deliveries of 42,247 vehicles, narrowly missing estimates, and said it will release results on Feb. 12 after markets close. Rivian is preparing to start deliveries of its lower-priced R2 SUV in the first half of 2026, a model expected to compete with Tesla’s Model Y.

Tesla’s energy storage numbers offered a counterweight to softer vehicle volumes. Investors have increasingly watched the division for signs that non-auto revenue can grow even when car demand cools.

What traders want next is clarity on pricing and margins. Any step-up in discounting to defend market share would likely show up in profitability before it shows up in deliveries.

Before Monday’s session, technicians will watch whether the stock holds the $435 area, Friday’s intraday low, after the post-deliveries selloff. The next near-term hurdle sits around $462, Friday’s session high.

Markets also get the Institute for Supply Management’s manufacturing purchasing managers index (PMI) at 10 a.m. ET on Monday, a survey that investors use as a quick read on factory demand. A PMI reading above 50 signals expansion, and big surprises can move bond yields that feed directly into growth-stock valuations.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Next Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

Go toTop